Panic-Buyers are Making Out As Biotech Recovers
Recap - The “Hold Your Nose, Buy the Panic” crowd is being vindicated as biotech recovers from a 2-month correction, and makes its way towards old highs. … Continue Reading
Read NowzFree
AbbVie’s Unwelcome Advances Rebuffed by Shire
Insights - Shire Plc (SHPG) confirmed before the open on Friday said that it has rejected a $46 billion bid from AbbVie (ABBV), which represented a 25% premium … Continue Reading
Read Now
Stem Cells Get a Break with StemCells’ Early AMD Results
Insights - StemCells, Inc. (STEM) announced on Thursday interim results from a phase 1/2 trial of its HuCNS-SC cells in dry age-related macular degeneration (AMD). The results are encouraging in a field that has … Continue Reading
Read Now
Insmed Gets Breakthrough Designation Based on Failed Study
Insights - Insmed (INSM) announced on Wednesday that the FDA has granted Arikayce (liposomal amikacin), the company’s lead product candidate, Breakthrough Therapy Designation (BTD) for refractory nontuberculous mycobacterial (NTM) lung … Continue Reading
Read Now
Investor Beware: Vivus Buyout Bid Fails to Materialize
Insights - It’s June 18, five days past a self-imposed deadline, and Aspen Investment Fund is nowhere to be seen with its alleged $640 million bid to buy Vivus, Inc. … Continue Reading
Read Now
Don’t Misunderstand EnteroMedics’ Positive Panel Vote
Insights - The U.S. FDA’s Advisory Gastroenterology and Urology Devices Panel (GUDP) voted on Tuesday 6 to 2 (one abstention) that the relative benefits of EnteroMedics’ (ETRM) VBLOC vagal blocking … Continue Reading
Read Now
Flamel Shakes Off Drug Rejection, Sets up Big Event for August
Insights - Flamel (FLML) quickly turned around a CRL received in late April for one of its pipeline drug candidates. That sets up a big event for August 6.
Read Now